中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HBV相关肝衰竭抗病毒治疗进展

何卫平 王慧芬

引用本文:
Citation:

HBV相关肝衰竭抗病毒治疗进展

基金项目: 

军队“十一五”中医药研发推广专项重大临床攻关课题(2006231001); 北京市首发基金重点课题(公示中); 

详细信息
  • 中图分类号: R512.6;R575.3

Research funding: 

 

  • [1]Yuan HJ, Yuen MF, Ka-Ho Wong D, et al.The relationship be-tween HBV-DNA levels and cirrhosis-related complications inChinese with chronic hepatitis B[J].J Viral Hepat, 2005, 12 (4) ∶373-379.
    [2]Van Zonneveld M, Honkoop P, Hansen BE, et al.Long-term fol-low-up of alpha-interferon treatment of patients with chornic hepa-titis B[J].Hepatology, 2004, 39 (3) ∶804-810.
    [3]Liaw YF, Sung JJ, Chow WC, et al.Lamivudine for patients withchronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) ∶1521-1531.
    [4]Di Marco V, Di Stefano R, Ferraro D, et al.HBV-DNA suppres-sion and disease course in HBVcirrhosis patients on long-tern lami-vudine therapy[J].Antivir Ther, 2005, 10 (3) ∶431-439.
    [5]Tseng PL, Lu SN, Tung HD, et al.Determinants of early mortalityand benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis[J].J Viral Hepat, 2005, 12 (4) ∶386-392.
    [6]Su GG, Zhao NF, Zhou Y, et al.Adefovir dipivoxil in treatment ofdecompensated liver cirrhosis patients with YMDD mutation[J].Zhe-jiang Da Xue Xue Bao Yi Xue Ban, 2005, 34 (5) ∶470-472.
    [7]Price JS, France AJ, Moaven LD, et al.Foscarnet in fulminant hep-atitis B[J].Lancet.1986, 2 (8518) ∶1273.
    [8]孙燕, 关琦, 李广明, 等.膦甲酸钠治疗重型乙型肝炎临床研究[J].医药论坛杂志, 2006, 27 (3) ∶64-65.
    [9]Tillmann HL, Hadem J, Leifeld L, et al.Safety and efficacy of lami-vudine in patients with severe acute or fulminant hepatitis B, a multi-center experience[J].J Viral Hepat, 2006, 13 (4) ∶256-263.
    [10]Chien RN, Lin CH, Liaw YF.The effect of lamivudine therapy inhepatic decompensation during acute exacerbation of chronic hepatitisB[J].J Hepatol, 2003, 38 (3) ∶322-327.
    [11]Tsang SW, Chan HL, Leung NW, et al.Lamivudine treatment forfulminant hepatic failure due to acute exacerbation of chronic hepati-tis B infection[J].Aliment Pharmacol Ther, 2001, 15 (11) ∶1737-1744.
    [12]Yuen MF, Sablon E, Hui CK, et al.Prognostic factors in severeexacerbation of chronic hepatitis B[J].CID, 2003, 36 (8) ∶978-984.
    [13]Tsubota A, Arase Y, Suzuki Y, et al.Lamivudine monotherapy forspontaneous severe acute exacerbation of chronic hepatitis B[J].JGastroenterol Hepatol, 2005, 20 (3) ∶426-432.
    [14]Lo CM, Liu CL, Lau GK, et al.Liver transplantation for chronichepatitis B with lamivudine-resistant YMDD mutant using add-onadefovir dipivoxil plus lamivudine[J].Liver Transpl, 2005, 11 (7) ∶807-813.
    [15]张南, 夏杰, 邓国宏, 等.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].第三军医大学学报, 2008, 30 (1) ∶75-77.
  • 加载中
计量
  • 文章访问数:  3218
  • HTML全文浏览量:  5
  • PDF下载量:  861
  • 被引次数: 0
出版历程
  • 出版日期:  2009-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回